|
|
Volumn 298, Issue 3, 2007, Pages 273-275
|
|
Cancer drug trials show modest benefit: Drugs target liver, gastric, head and neck cancers
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;
ANTINEOPLASTIC AGENT;
CARBOPLATIN;
CETUXIMAB;
CISPLATIN;
FLUOROURACIL;
IRINOTECAN;
SORAFENIB;
ADVANCED CANCER;
CANCER CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER MORTALITY;
CANCER SURVIVAL;
CLINICAL TRIAL;
COLORECTAL CANCER;
HEAD AND NECK CANCER;
HEPATITIS B;
HEPATITIS C;
HUMAN;
LIVER CELL CARCINOMA;
LIVER CIRRHOSIS;
MULTIPLE CYCLE TREATMENT;
PRIORITY JOURNAL;
SHORT SURVEY;
SQUAMOUS CELL CARCINOMA;
STOMACH CANCER;
SURVIVAL TIME;
UNSPECIFIED SIDE EFFECT;
|
|
EID: 34447518802
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.298.3.273 Document Type: Short Survey |
|
Times cited : (13)
|
|
References (0)
|